1. Introduction {#sec1-biomolecules-07-00079}
===============

The ultimate goal of periodontal therapy is to eliminate supragingival and subgingival plaque and arrest the progression of periodontal disease. Scaling and root planing (SRP) are considered as the gold standard for the treatment of chronic periodontitis. Although many studies have shown significant improvements following SRP, complete elimination of subgingival periodontal pathogens and irritants is not always possible \[[@B1-biomolecules-07-00079],[@B2-biomolecules-07-00079]\]. Residual pockets during SRP present similar challenges and additional therapeutic approaches to achieving periodontal health are required. To improve the results of mechanical debridement, antibiotics are widely used \[[@B3-biomolecules-07-00079],[@B4-biomolecules-07-00079]\]. Limitations of drug resistance associated with the use of local and systemic medications have led to the popularity of antimicrobial photodynamic therapy (aPDT) in the management of chronic periodontitis. aPDT was introduced in 1904 as the light-induced inactivation of cells, microorganisms or molecules. This treatment modality is based on the principle that a photoactivatable substance, called a photosensitizer, is activated by the light of a particular wavelength. The transfer of energy causes the formation of free radicals of singlet oxygen, which exert destructive action on bacteria and their products \[[@B5-biomolecules-07-00079],[@B6-biomolecules-07-00079]\].

Even though the effects of photodynamic action have been known for a long time, interest in its practical use has increased only in the last few years. Because several studies had shown that killing both Gram-positive and Gram-negative bacteria is possible, Wilson's group in London investigated different aspects of the application of aPDT in dentistry in vitro and in vivo \[[@B7-biomolecules-07-00079],[@B8-biomolecules-07-00079],[@B9-biomolecules-07-00079]\]. In the presence of various types of photosensitizers, such as toluidine blue O and methylene blue, several periodontal pathogens are found to be susceptible to red lasers, which points to the fact that aPDT could be could be advantageous in periodontal therapy \[[@B10-biomolecules-07-00079]\]. However, randomized controlled trials and systematic reviews have shown contrasting results regarding the efficacy of aPDT in chronic periodontitis \[[@B10-biomolecules-07-00079],[@B11-biomolecules-07-00079],[@B12-biomolecules-07-00079],[@B13-biomolecules-07-00079],[@B14-biomolecules-07-00079],[@B15-biomolecules-07-00079],[@B16-biomolecules-07-00079]\]. Hence, the objective of the systematic review was to determine the effectiveness of aPDT as a primary mode or as an adjunct to non-surgical periodontal therapy.

2. Methodology {#sec2-biomolecules-07-00079}
==============

2.1. Search Strategy {#sec2dot1-biomolecules-07-00079}
--------------------

The search strategy was based on the question "Is aPDT as either a primary mode of treatment or an adjunct to non-surgical treatment more effective than SRP alone in chronic periodontitis in terms of clinical attachment level (CAL) gain and probing depth (PD) reduction?". This focused question was developed using the Patient, Intervention, Comparison, and Outcome (PICO) format \[[@B17-biomolecules-07-00079]\]. Two authors independently searched the Medline, EMBASE, Cochrane Library, Web of Science, Google Scholar, and Scopus databases from January 2008 to December 2016 for relevant studies. The following terms in various combinations were used: bacteria, diode laser, lethal photosensitization, photodynamic inactivation, photodynamic antimicrobial chemotherapy, photodynamic therapy, and periodontitis.

2.2. Eligibility and Information Sources {#sec2dot2-biomolecules-07-00079}
----------------------------------------

The 20 studies included in this systematic review were randomized clinical trials (RCTs) or quasi-RCTs of aPDT compared to placebo, no intervention, or non-surgical treatment in an adult population ([Figure 1](#biomolecules-07-00079-f001){ref-type="fig"}). In all studies, aPDT was either a primary mode of therapy or an adjunct to other non-surgical treatments, with CAL and/or PD as the primary outcome measures. Studies of aPDT used for the treatment of periodontitis at any dosage or duration were included. Eligible control interventions that were considered for this systematic review were placebo, no treatment, or non-surgical periodontal treatment (independent of or as adjunct therapy). Letters to the editor, short commentaries, and review articles were excluded.

2.3. Study Selection and Data Collection {#sec2dot3-biomolecules-07-00079}
----------------------------------------

To minimize the potential for reviewer bias, two blinded reviewers independently screened all titles and abstracts identified through electronic and manual searches. Disagreements regarding the inclusion or exclusion of studies were resolved by a discussion between the reviewers. Two reviewers used an extraction form to categorize the included articles in terms of patient demographic characteristics, presence of smokers, laser settings, and reported outcomes measures. The quality of the studies included in the systematic review was determined separately by two independent reviewers.

3. Results {#sec3-biomolecules-07-00079}
==========

3.1. Study Characteristics {#sec3dot1-biomolecules-07-00079}
--------------------------

The mean age of patients in the studies included in this review ranged from 39.6 years to 62.8 years. Studies that recruited patients with chronic periodontitis were included in this review. The characteristics of the included studies are shown in [Table 1](#biomolecules-07-00079-t001){ref-type="table"}. Criteria of chronic periodontitis \[[@B12-biomolecules-07-00079]\], severe periodontitis \[[@B18-biomolecules-07-00079]\], pocket depth ≥5 mm \[[@B19-biomolecules-07-00079],[@B20-biomolecules-07-00079],[@B21-biomolecules-07-00079],[@B22-biomolecules-07-00079]\], untreated periodontal pockets \[[@B12-biomolecules-07-00079]\], pocket depth between 4 and 6 mm \[[@B23-biomolecules-07-00079],[@B24-biomolecules-07-00079]\], pocket depth between 5 and 9 mm \[[@B25-biomolecules-07-00079]\], and residual pockets during supportive periodontal therapy \[[@B13-biomolecules-07-00079],[@B26-biomolecules-07-00079],[@B27-biomolecules-07-00079],[@B28-biomolecules-07-00079],[@B29-biomolecules-07-00079],[@B30-biomolecules-07-00079]\] were used. The presence of *Fusobacterium nucleatum* in localized chronic periodontitis was an inclusion criterion in one study \[[@B31-biomolecules-07-00079]\]. Most of the studies included either single-rooted teeth or both single- and multi-rooted teeth, while two studies reported the effects of aPDT only in multi-rooted teeth \[[@B19-biomolecules-07-00079],[@B32-biomolecules-07-00079]\]. Most of the remaining studies evaluated aPDT as both an adjunct to SRP in the management of chronic periodontitis and a monotherapy \[[@B24-biomolecules-07-00079],[@B26-biomolecules-07-00079],[@B27-biomolecules-07-00079],[@B30-biomolecules-07-00079]\].

3.2. Study Design {#sec3dot2-biomolecules-07-00079}
-----------------

The included studies were RCTs published between 2008 and 2015. Of the 20 studies included, six were parallel two-arm \[[@B12-biomolecules-07-00079],[@B13-biomolecules-07-00079],[@B19-biomolecules-07-00079],[@B23-biomolecules-07-00079],[@B30-biomolecules-07-00079],[@B31-biomolecules-07-00079]\], one was parallel three-arm \[[@B27-biomolecules-07-00079]\], one was a split-mouth four-arm \[[@B24-biomolecules-07-00079]\], five were split-mouth three-arm \[[@B20-biomolecules-07-00079],[@B25-biomolecules-07-00079],[@B26-biomolecules-07-00079],[@B28-biomolecules-07-00079],[@B29-biomolecules-07-00079]\], and six were split-mouth two-arm studies \[[@B11-biomolecules-07-00079],[@B18-biomolecules-07-00079],[@B21-biomolecules-07-00079],[@B22-biomolecules-07-00079],[@B32-biomolecules-07-00079],[@B34-biomolecules-07-00079]\]. In vitro studies, in vivo studies with animals, and clinical reports were excluded. In split-mouth RCTs, each subject is its own control, and most of the variability of outcome among patients is removed from the intervention effect estimate. Bias may be induced \[[@B35-biomolecules-07-00079]\] due to the "spilling" of the effects of one therapy from one site to another. When evaluating the results of aPDT in split-mouth studies, the paired nature of the data must be taken into account \[[@B36-biomolecules-07-00079]\]. Because every subject receives each intervention, the split-mouth design may be better suited to studies that determine patient preferences.

3.3. Sample Size and Calculation {#sec3dot3-biomolecules-07-00079}
--------------------------------

The sample sizes ranged from 15 to 90, with all studies but four having more female participants than males \[[@B12-biomolecules-07-00079],[@B21-biomolecules-07-00079],[@B27-biomolecules-07-00079],[@B28-biomolecules-07-00079]\]. Of the 29 studies, 13 reported on the calculation of sample size with the power of the study set at or above 80% (81--86). Among these, nine studies reported that sample size was calculated based on probing depth, while five used CAL as the primary outcome. Significant changes reported in the studies must be interpreted with caution because to detect even a moderate change, at least 40 patients may be needed in one arm of the treatment. Generally, 20% is added to compensate for any drop-outs. The sample size is calculated as the number of patients needed for one arm, but few studies adhered to that. The lack of sample size calculation and reported methods of randomization were the main methodological issues noted. The reasons for drop-outs were also not specified in most of the studies.

3.4. Blinding {#sec3dot4-biomolecules-07-00079}
-------------

Blinding is done in order to decrease or hide the information regarding the type of intervention given to a particular participant so that outcomes and assessments of outcomes are unaffected. In this review, eight studies were double-blinded, eight were single-blinded, and four did not mention the type of blinding. The examiner and biostatistician were blinded in these trials. Details are provided in [Table 2](#biomolecules-07-00079-t002){ref-type="table"}.

3.5. Smokers {#sec3dot5-biomolecules-07-00079}
------------

Smoking has been associated with an increased occurrence of periodontitis. [Table 1](#biomolecules-07-00079-t001){ref-type="table"} shows that four of the 19 studies included both smokers and non-smokers \[[@B13-biomolecules-07-00079],[@B27-biomolecules-07-00079],[@B28-biomolecules-07-00079],[@B29-biomolecules-07-00079]\]. Of these, two showed an improved reduction in PD compared with a control group \[[@B27-biomolecules-07-00079],[@B29-biomolecules-07-00079]\]. When interpreting the results, it should be noted that an intention-to-treat analysis was not mentioned in a few studies. Studies by Cappuyns et al. \[[@B29-biomolecules-07-00079]\] and Chondros et al. \[[@B13-biomolecules-07-00079]\] included smokers and showed microbiological improvement, while immunological profiles were found to be improved in the study by Campanile et al. \[[@B27-biomolecules-07-00079]\]. In this study, although detection frequencies of periodontal pathogens did not change significantly from baseline to month 3 or 6 in any group, significant overall decreases were observed from baseline to month 6 for C-reactive protein, serum amyloid A, fibrinogen, procalcitonin, and α-2 macroglobulin. Single or double episodes of aPDT showed some additional benefit over ultrasonic instrumentation alone.

3.6. Photosensitizing Agents and Wavelengths Used in aPDT {#sec3dot6-biomolecules-07-00079}
---------------------------------------------------------

Antimicrobial photodynamic therapy has been applied using various combinations of lasers and photosensitizing (PS) agents. Methylene blue (3,7-bis(dimethyl-amino) phenazathionium chloride tetramethylthionine chloride)) was the most commonly used photosensitizing dye in the clinical trials. Toluidine blue O was also reported \[[@B24-biomolecules-07-00079],[@B25-biomolecules-07-00079],[@B30-biomolecules-07-00079]\]. [Table 3](#biomolecules-07-00079-t003){ref-type="table"} shows the laser settings of the included studies. Toluidine blue O and methylene blue have similar chemical and physicochemical characteristics and have been used previously to detect mucosal tumors or atypical epithelia because they do not stain normal mucosa. They are the PS agents of choice for aPDT because they have a pronounced cationic charge that helps them bind to the outer membrane of Gram-negative bacteria and penetrate bacterial cells, thereby demonstrating a high degree of selectivity for killing microorganisms compared with host mammalian cells \[[@B37-biomolecules-07-00079],[@B38-biomolecules-07-00079]\]. These dyes have been used in various concentrations (1 mg/mL to 10 mg/mL) with a residence time of 1 to 5 min in the periodontal pocket. Only two studies reported the quantity of PS used, which was either 0.2 mL methylene blue or 1 mL \[[@B25-biomolecules-07-00079],[@B27-biomolecules-07-00079]\]. After a resident period of 1 to 3 min, excess PS was flushed off so that it would not act as an optical shield during laser irradiation \[[@B23-biomolecules-07-00079]\].

Diode lasers between the wavelength of 635 nm and 670 nm were commonly used, although wavelengths of 808 nm \[[@B20-biomolecules-07-00079]\] and 940 nm \[[@B22-biomolecules-07-00079]\] were used in some studies. Optical fiber applicators with various diameters, ranging from 200 μm to 750 μm, were used. The laser application time was generally 60 s, although application times of 30 s \[[@B22-biomolecules-07-00079]\] and 150 s \[[@B25-biomolecules-07-00079]\] were also reported. Laser energy between 3 J/cm^2^ and 320 J/cm^2^ was used. The large differences in these laser parameters make it impossible to compare the results reported by various studies.

Wavelength and energy density are both important factors in the efficacy of lasers, and wavelength and optimal dose with an appropriate photosensitizer are practical variables in the bactericidal process \[[@B40-biomolecules-07-00079]\]. It appears that differences in these factors led to different results.

3.7. Frequency of aPDT Application {#sec3dot7-biomolecules-07-00079}
----------------------------------

Most of the studies included used a single session of aPDT, but some \[[@B22-biomolecules-07-00079],[@B24-biomolecules-07-00079],[@B27-biomolecules-07-00079]\] used multiple applications ([Table 3](#biomolecules-07-00079-t003){ref-type="table"}). The results of these studies on the effects of aPDT in terms of pocket depth reduction and clinical attachment gain differ. Two of the three studies that applied aPDT more than once showed improvements in clinical parameters compared to the control group \[[@B22-biomolecules-07-00079],[@B27-biomolecules-07-00079]\]. These two studies also showed improvements in both immunological and microbiological parameters, which could be related to the repeated use of aPDT. De Paula Eduardo et al. \[[@B41-biomolecules-07-00079]\] found that the application of multiple laser treatments is more effective than a single treatment. Multiple uses of aPDT during the first weeks of treatment may have increased the antimicrobial effect. One study \[[@B42-biomolecules-07-00079]\] mentioned that the short time of exposure to light can be one reason for aPDT's lack of effect.

3.8. Effect of aPDT on Clinical Parameters {#sec3dot8-biomolecules-07-00079}
------------------------------------------

Primary outcome measures were probing pocket depth reduction and CAL gain, which were defined as the difference between PD and CAL levels, respectively, at baseline and at the end of the follow-up period \[[@B33-biomolecules-07-00079],[@B43-biomolecules-07-00079]\]. A change in bleeding on probing was the most common secondary outcome among the clinical parameters \[[@B44-biomolecules-07-00079]\]. Microbiologic and immunologic changes, any adverse effect reported by the authors, and patient-based outcome measures were also studied \[[@B45-biomolecules-07-00079]\]. All studies included in this review evaluated the effect of aPDT on clinical parameters ([Table 2](#biomolecules-07-00079-t002){ref-type="table"}). Changes in PD and CAL were reported in all studies. While nine studies \[[@B11-biomolecules-07-00079],[@B21-biomolecules-07-00079],[@B22-biomolecules-07-00079],[@B23-biomolecules-07-00079],[@B27-biomolecules-07-00079],[@B31-biomolecules-07-00079],[@B32-biomolecules-07-00079],[@B33-biomolecules-07-00079],[@B34-biomolecules-07-00079]\] reported improvements in PD following aPDT, the remaining studies did not report any additional benefit of aPDT compared to SRP \[[@B12-biomolecules-07-00079],[@B13-biomolecules-07-00079],[@B18-biomolecules-07-00079],[@B19-biomolecules-07-00079],[@B20-biomolecules-07-00079],[@B24-biomolecules-07-00079],[@B25-biomolecules-07-00079],[@B26-biomolecules-07-00079],[@B28-biomolecules-07-00079],[@B29-biomolecules-07-00079],[@B30-biomolecules-07-00079]\]. These outcome parameters were re-evaluated at various time intervals, ranging from two weeks to one year. The results must be interpreted carefully as various factors could affect the results of aPDT. Pressure-calibrated probes \[[@B11-biomolecules-07-00079]\] and examiner calibrations \[[@B12-biomolecules-07-00079],[@B13-biomolecules-07-00079],[@B18-biomolecules-07-00079],[@B19-biomolecules-07-00079],[@B20-biomolecules-07-00079],[@B23-biomolecules-07-00079],[@B24-biomolecules-07-00079],[@B25-biomolecules-07-00079],[@B26-biomolecules-07-00079],[@B32-biomolecules-07-00079]\] were used in several studies for standardization.

3.9. Antimicrobial Effect of aPDT in Chronic Periodontitis {#sec3dot9-biomolecules-07-00079}
----------------------------------------------------------

Pathogenic periodontal microorganisms such as *Porphyromonas gingivalis*, *Prevotella intermedia*, *Fusobacterium nucleatum*, and *Parvimonas micra* have been destroyed by photodynamic action \[[@B46-biomolecules-07-00079]\]. The reduction of the biological activities of the key virulence factors, such as lipopolysaccharide and proteases, may act as an additional benefit. In comparison, microbiological changes were not well evaluated, as shown in [Table 4](#biomolecules-07-00079-t004){ref-type="table"}. Only eight of the 20 studies reported microbiological changes. Six of these \[[@B13-biomolecules-07-00079],[@B19-biomolecules-07-00079],[@B25-biomolecules-07-00079],[@B29-biomolecules-07-00079],[@B31-biomolecules-07-00079],[@B33-biomolecules-07-00079]\] reported a reduction in periodontal pathogens in the test group at various time intervals. Clinical improvements along with microbiological changes were observed in two studies \[[@B29-biomolecules-07-00079],[@B31-biomolecules-07-00079]\]. PCR was used in all studies but one to detect the microbiological changes; in that study, RNA probes were used \[[@B29-biomolecules-07-00079]\]. Sigusch et al. \[[@B31-biomolecules-07-00079]\] studied *Fusobacterium nucleatum*-infected chronic periodontitis patients. Other organisms that were evaluated included *Eubacteriumnodatum* \[[@B13-biomolecules-07-00079]\], *Porphyromonas gingivalis*, *Aggregatibacter actinomycetemcomitans*, *Tannerella forsythia*, *Treponema denticola*, *Prevotella intermedia*, *Parvimonasmicra*, *Fusobacterium nucleatum*, *Eikenellacorrodens*, and *Capnocytophaga* sp. \[[@B19-biomolecules-07-00079],[@B25-biomolecules-07-00079],[@B29-biomolecules-07-00079]\]. Significant reductions were observed in the levels of *F. nucleatum* \[[@B13-biomolecules-07-00079],[@B31-biomolecules-07-00079]\], *E. nodatum* \[[@B13-biomolecules-07-00079]\], *P. gingivalis*, *T. forsythia*, *T. denticola* \[[@B29-biomolecules-07-00079]\], and *E. corrodens* \[[@B25-biomolecules-07-00079]\]. The mechanism through which aPDT kills microorganisms such as *P. gingivalis* and *F. nucleatum* has been established \[[@B47-biomolecules-07-00079]\]. The lethal photosensitization of these microorganisms must involve changes in membranes and/or plasma membrane proteins and DNA damage mediated by singlet oxygen \[[@B47-biomolecules-07-00079]\].

3.10. Effect of Immunological Parameters Following aPDT {#sec3dot10-biomolecules-07-00079}
-------------------------------------------------------

Five studies reported improvements in immunological parameters \[[@B19-biomolecules-07-00079],[@B22-biomolecules-07-00079],[@B26-biomolecules-07-00079],[@B27-biomolecules-07-00079],[@B28-biomolecules-07-00079]\], as shown in [Table 4](#biomolecules-07-00079-t004){ref-type="table"}. Improvements in levels of Interleukin (IL)-1b and IL-6, IL-4 \[[@B22-biomolecules-07-00079]\], C-reactive protein, serum amyloid A, fibrinogen, procalcitonin, α-2 macroglobulin \[[@B27-biomolecules-07-00079]\], granulocyte macrophage colony-stimulating factor (GM-CSF), interferon, IL-8 \[[@B19-biomolecules-07-00079]\] were reported. Among these, only one study also showed clinical improvement \[[@B27-biomolecules-07-00079]\]. It should be noted that in this study, aPDT was administered twice a week. A significant overall decrease was observed from baseline to month 6 for C-reactive protein, serum amyloid A, fibrinogen, procalcitonin, and α-2 macroglobulin. When looking at the groups separately, C-reactive protein was significantly lower only when the laser had been activated twice. Other differences between groups were not significant.

3.11. Patient-Based Outcome Measures Reported in the Studies {#sec3dot11-biomolecules-07-00079}
------------------------------------------------------------

Traditional measures of health outcomes do not capture patients' perspectives of the disease, and therefore, patient-based outcomes were identified as a research priority \[[@B48-biomolecules-07-00079]\]. [Table 3](#biomolecules-07-00079-t003){ref-type="table"} shows that only four studies reported patients' perspectives of aPDT. Three of these studies \[[@B26-biomolecules-07-00079],[@B27-biomolecules-07-00079],[@B29-biomolecules-07-00079]\] report pain perceptions of patients during the procedure using the visual analogue scale (VAS). In the study by Kolbe et al. \[[@B26-biomolecules-07-00079]\] there were no differences in VAS scores between protocols for any of the parameters described. SRP-treated sites required significantly more anesthesia than did those treated with other therapies. Cappuyns et al. \[[@B29-biomolecules-07-00079]\] reported that scores \> 40 mm were similar in all treatment groups, and the tendency for more frequent VAS scores \> 30 mm after SRP did not reach statistical significance. The total treatment time per quadrant, the use of local anesthetics, and the sequence of the treatments had no significant impact. Campanile et al. \[[@B27-biomolecules-07-00079]\] reported patient discomfort following aPDT in periodontitis. It was found that only two of 27 patients being treated for residual periodontal pockets reported pain \> 40 mm on a 0--100 mm VAS scale. Neither case was directly related to the aPDT procedure. One was due to tabmechanical debridement and another to a feeling of illumination in the eye when a pocket mesial of a first maxillary molar was irradiated. Halitosis as perceived by patients following the treatment was reported in one study \[[@B23-biomolecules-07-00079]\]. Halitosis as detected by the hand-over-mouth technique was found to be improved after one month of treatment and did not persist beyond that time. There is increasing evidence that this treatment modality enhances wound healing following mechanical debridement by decontamination and tissue stimulation \[[@B49-biomolecules-07-00079]\]. The latest studies have also shown that a combination of SRP and PDT results in substantially higher short-term clinical improvements, evidenced by probing depth or bleeding on probing reductions compared with SRP alone \[[@B49-biomolecules-07-00079]\], including short-term reduction in *A. actinomycetemcomitans* levels in treating residual pockets after 3 months \[[@B46-biomolecules-07-00079]\].

4. Conclusions {#sec4-biomolecules-07-00079}
==============

aPDT is emerging as a beneficial therapeutic option in the treatment of periodontitis. The results of many studies, if not all, indicate that aPDT along with SRP has a clear-cut advantage in the treatment of periodontitis. The additional benefits of aPDT in terms of clinical, microbiological, immunological, and patient-based outcomes are definitely encouraging and, hence, should be included in the routine treatment protocol of patients with periodontitis. Although there was a wide range of heterogeneity in the included studies, they all indicated that aPDT has the potential to be an effective adjunct in the treatment of chronic periodontitis. Long-term, multicenter studies with larger sample sizes are needed before aPDT can be recommended as an effect treatment modality.
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###### 

Studies on aPDT in chronic periodontitis with clinical attachment level (CAL) or probing depth (PD) as the primary outcome measures.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author\                                                    Sample Size (Male/Female) and Mean Age   Study design; Power of Study; Case Allotment   Outcome Measured                                                                                                                                                      Treatment Arms                                                             Conclusion
  Country                                                                                                                                                                                                                                                                                                                                                                                             
  ---------------------------------------------------------- ---------------------------------------- ---------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Kolbe et al. \[[@B26-biomolecules-07-00079]\]\             22 (10/12)\                              Split-mouth\                                   Clinical, Microbiology (polymerase chain reaction(PCR)); Pain perception (Visual Analogue Scale (VAS))                                                                Scaling and Root Planing (SRP)\                                            All therapies promoted similar improvements in clinical parameters. The aPDT protocol presented inferior frequency of *Porphyromonas gingivalis* at three months when compared with the other therapies. aPDT as an exclusive therapy may be considered a non-invasive alternative for treating residual pockets and offers advantages in the modulation of cytokines.
  Brazil                                                     48.52 y                                  83% (CAL) Computer-generated                                                                                                                                                                                         aPDT\                                                                      
                                                                                                                                                                                                                                                                                                                           Photosensitizer                                                            

  Carvalho et al. \[[@B33-biomolecules-07-00079]\]\          34 (21/13)\                              Parallel                                       Pocket probing depth (PPD), CAL, bleeding on probing (BoP) and plaque index (PI)                                                                                      SRP\                                                                       Both treatments resulted in significant clinical improvement in patients with residual periodontal pockets. We did not find any additional significant benefit of PDT in terms of PPD, CAL, BoP, or pathogen level reduction.
  Brazil                                                     48 y                                                                                                                                                                                                                                                          aPDT                                                                       

  Betsy et al. \[[@B23-biomolecules-07-00079]\]\             90 (39/51)\                              Parallel\                                      Clinical and halitosis as perceived by patient                                                                                                                        SRP\                                                                       PD improved after three months and halitosis after one month. Statistically significant improvements in the gingival index and gingival bleeding index were observed for the test group after two weeks and one month of aPDT, respectively. aPDT is a beneficial adjunct to SRP in the non-surgical treatment and management of chronic periodontitis in the short term.
  India                                                      39.6 y                                   80% (PD) Tippet's 2-digit number table                                                                                                                                                                               SRP + aPDT                                                                 

  Luchesi et al. \[[@B19-biomolecules-07-00079]\]\           37\                                      Parallel\                                      Clinical, Microbiology (PCR); Immunology (granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon (IFN), Interleukin (IL)-6 and Interleukin-8 levels)   SRP + aPDT\                                                                Clinical parameters improved after both therapies. Did not promote clinical benefits for class II furcations; however, there were advantages in terms of the local levels of cytokines and periodontopathogens reduction.
  Brazil                                                     50.5 y                                   86% (CAL) Computer-generated                                                                                                                                                                                         SRP + non-activated light (only PS)                                        

  Dilsiz et al. \[[@B20-biomolecules-07-00079]\]\            24 (10/14)\                              Split-mouth\                                                                                                                                                                                                         SRP\                                                                       Improvement in PD and CAL gain following treatment. Additional use of potassium titanyl phosphate (KTP) laser was found to be better in improving clinical parameters than conventional periodontal therapy of deeper pockets.
  Turkey                                                     40.7 y                                   Computer-generated                                                                                                                                                                                                   SRP + aPDT\                                                                
                                                                                                                                                                                                                                                                                                                           SRP + KTP                                                                  

  Alwaeli et al. \[[@B32-biomolecules-07-00079]\]\           21 (7/14)\                               Split-mouth\                                                                                                                                                                                                         SRP\                                                                       Significant improvement in all evaluated clinical parameters for at least one year. There were significantly greater reductions and gains for SRP + aPDT than for SRP at all three-time points. aPDT as an adjunctive therapy to SRP represents a promising therapeutic concept for persistent periodontitis.
  Malaysia                                                   40.9 y                                   Computer-generated                                                                                                                                                                                                   SRP + aPDT                                                                 

  Campanile et al. \[[@B27-biomolecules-07-00079]\]\         27 (14/13)\                              Parallel\                                      Clinical, Microbiology (PCR); Pain perception (VAS); Immunology (C-reactive protein, Serum amyloid A, fibrinogen, procalcitonin, and α-2 macroglobulin)               aPDT twice in one week\                                                    Significant PD and BoP reduction after three months when aPDT was administered twice a week. C-reactive protein was significantly lower only when the laser had been activated twice.
  Switzerland                                                62.8 y                                   Smokers included\                                                                                                                                                                                                    aPDT once\                                                                 
                                                                                                      80% (PD)\                                                                                                                                                                                                            Sham without active light                                                  
                                                                                                      Computer-generated                                                                                                                                                                                                                                                                              

  Bassir et al. \[[@B24-biomolecules-07-00079]\]\            16 (8/8)\                                Split-mouth\                                   Clinical                                                                                                                                                              LED\                                                                       No additional benefit was noticed with administration of photoactivated disinfection (PAD) using LED in patients with moderate to severe chronic periodontitis.
  USA                                                        50.3 y                                   80% (CAL)\                                                                                                                                                                                                           PS\                                                                        
                                                                                                      Computer-generated                                                                                                                                                                                                   aPDT\                                                                      
                                                                                                                                                                                                                                                                                                                           SRP                                                                        

  Campos et al. \[[@B34-biomolecules-07-00079]\]\            15 (8/7)\                                Split-mouth\                                   Clinical                                                                                                                                                              SRP\                                                                       aPDT as an adjunctive to mechanical debridement demonstrated additional clinical benefits for residual pockets in single-rooted teeth and may be an alternative therapeutic strategy in supportive periodontal maintenance.
  Brazil                                                     48.1 y                                   80% (PD)\                                                                                                                                                                                                            SRP + aPDT                                                                 
                                                                                                      Computer-generated                                                                                                                                                                                                                                                                              

  Balata et al. \[[@B18-biomolecules-07-00079]\]\            22 (8/14)\                               Split-mouth\                                   Clinical                                                                                                                                                              SRP\                                                                       Both approaches resulted in significant clinical improvement in the treatment of severe chronic periodontitis. aPDT did not provide any additional benefit.
  Brazil                                                     43.18 y                                  80% (CAL)\                                                                                                                                                                                                           SRP + aPDT                                                                 
                                                                                                      Coin toss                                                                                                                                                                                                                                                                                       

  Barekdar et al. \[[@B21-biomolecules-07-00079]\]\          22 (12/10)\                              Split-mouth                                    Clinical                                                                                                                                                              SRP\                                                                       A greater reduction of the PD was achieved by a combination of SRP/aPDT; therefore, aPDT is suitable as an adjuvant therapy.
  Germany                                                    59.3 y                                                                                                                                                                                                                                                        SRP + aPDT                                                                 

  Giannopoulou et al. \[[@B28-biomolecules-07-00079]\]\      32 (23/9)\                               Split-mouth\                                   Clinical, Immunology (IL-17, basic fibroblast growth factor, granulocyte-macrophage colony-stimulating factor (GCSF), macrophage inflammatory protein (MIP))          SRP\                                                                       No significant differences were observed among the three treatment modalities at any time point for any biochemical parameter or enhanced expression of inflammatory mediators.
  Switzerland                                                52 y                                     Smokers included\                                                                                                                                                                                                    Diode laser\                                                               
                                                                                                      80% (PD)\                                                                                                                                                                                                            aPDT                                                                       
                                                                                                      Computer-generated                                                                                                                                                                                                                                                                              

  Cappuyns et al. \[[@B29-biomolecules-07-00079]\]\          32 (23/9)\                               Split-mouth\                                   Clinical, Microbiology (RNA probes); Pain perception (VAS)                                                                                                            SRP\                                                                       At the end of six months, statistically significant PD and BoP reductions were recorded. Frequencies of three periodontal pathogens were significantly lower in groups with aPDT- and SRP-treated than in diode soft laser-treated quadrants after 14 days. However, the same was not noticed at the end of two and six months. aPDT resulted in a reduction in the number of pockets after six months.
  Switzerland                                                52 y                                     Smokers included\                                                                                                                                                                                                    Diode laser\                                                               
                                                                                                      80% (PD)\                                                                                                                                                                                                            aPDT                                                                       
                                                                                                      Computer-generated                                                                                                                                                                                                                                                                              

  Lui et al. \[[@B22-biomolecules-07-00079]\]\               24 (10/14)\                              Split-mouth                                    Clinical, Immunology (IL-1b levels in gingival crevicular fluid)                                                                                                      SRP\                                                                       The test teeth achieved greater reductions in the percentage of sites with bleeding on probing and in mean probing depth at one month compared with the control teeth and also greater reduction of interleukin (IL)-1b levels in gingival crevicular fluid at 1 week than did the control sites. No significant differences in periodontal parameters were found between the test and control teeth at three months.
  Hong Kong                                                  50 y                                                                                                                                                                                                                                                          SRP + one course of low level laser therapy (LLT) and aPDT within 5 days   

  Theodoro et al. \[[@B25-biomolecules-07-00079]\]\          33 (12/21)\                              Split-mouth\                                   Clinical, Microbiology (PCR)                                                                                                                                          SRP\                                                                       All treatment groups showed an improvement in all clinical parameters and a significant reduction in the proportion of sites positive for periodontopathogens at 60, 90, and 180 days compared to baseline. None of the periodontal parameters showed a significant difference among the groups. At 180 days, aPDT treatment led to a significant reduction in the percentage of sites positive for all bacteria compared to SRP alone.
  Brazil                                                     43.12 y                                  81% (CAL)\                                                                                                                                                                                                           SRP + Toluidine Blue O (TBO)\                                              
                                                                                                      Computer-generated                                                                                                                                                                                                   SRP + aPDT                                                                 

  Sigush et al. \[[@B31-biomolecules-07-00079]\]\            24 (7/17)\                               Parallel\                                      Clinical, Microbiology (PCR)                                                                                                                                          SRP + PS\                                                                  Significant reductions in reddening, BoP, and mean PD and CAL were observed during the observation period and with respect to controls. Appropriate to reduce periodontal inflammation and to successfully treat infection with *Fusobacterium nucleatum*.
  Germany                                                    42.7 y                                   Drawing lots                                                                                                                                                                                                         SRP + aPDT                                                                 

  Ruhling et al. \[[@B30-biomolecules-07-00079]\]\           60\                                      Parallel\                                                                                                                                                                                                            SRP\                                                                       aPDT was not found to be better than routine mechanical debridement in the management of persistent pockets, but still maybe considered a valuable therapeutic option.
  Germany                                                    48 y                                     80% (PD)\                                                                                                                                                                                                            aPDT                                                                       
                                                                                                      Computer-generated                                                                                                                                                                                                                                                                              

  Christodoulides et al. \[[@B12-biomolecules-07-00079]\]\   24 (13/11)\                              Parallel\                                                                                                                                                                                                            SRP\                                                                       Additional application of a single episode of aPDT to SRP failed to result in an additional improvement in terms of PD reduction and CAL gain, but resulted in a significantly higher reduction in bleeding scores compared to SRP alone.
  Germany                                                    45 y                                     80% (PD)\                                                                                                                                                                                                            SRP + aPDT                                                                 
                                                                                                      Coin toss                                                                                                                                                                                                                                                                                       

  Braun et al. \[[@B11-biomolecules-07-00079]\]\             20 (9/11)\                               Split-mouth                                                                                                                                                                                                          SRP\                                                                       Improvement in clinical parameters with the use of adjunctive aPDT as compared to subgingival debridement.
  Germany                                                    46.6 y                                                                                                                                                                                                                                                        SRP + aPDT                                                                 

  Chondros et al. \[[@B13-biomolecules-07-00079]\]\          24 (10/14)\                              Parallel\                                      Clinical, Microbiology (PCR)                                                                                                                                          SRP\                                                                       Additional application of a single episode of aPDT to SRP failed to result in additional improvement. Significantly higher reduction of bleeding scores in test group. At three months and six months, a statistically significantly higher improvement of BoP was found in the test group. At three months after therapy, the microbiological analysis showed a statistically significant reduction of *F.nucleatum* and *Eubacterium nodatum* in the test group.
  Germany                                                    49.3 y                                   80% (PD)\                                                                                                                                                                                                            SRP + aPDT                                                                 
                                                                                                      Coin toss                                                                                                                                                                                                                                                                                       
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

biomolecules-07-00079-t002_Table 2

###### 

The sample size and method used to derive samples in the selected studies.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author\                                                    Sample Size (Male/Female)   Power of the Study   Type of Randomization            Type of Blinding   Case Allotment                  Whether Intention-to-Treat (ITT) Analysis Done
  Country                                                                                                                                                                                         
  ---------------------------------------------------------- --------------------------- -------------------- -------------------------------- ------------------ ------------------------------- ------------------------------------------------
  Kolbe et al. \[[@B26-biomolecules-07-00079]\]\             22 (10/12)                  83% (CAL)            Not mentioned                    Double-blinded     Computer-generated              Yes
  Brazil                                                                                                                                                                                          

  Carvalho et al. \[[@B33-biomolecules-07-00079]\]\          34 (21/13)                  90% (CAL)            Block randomization (size = 4)   Double -blinded    Computer-generated              Yes
  Brazil                                                                                                                                                                                          

  Betsy et al. \[[@B23-biomolecules-07-00079]\]\             90 (39/51)                  80% (PD)             Block randomization (size = 4)   Double-blinded     Tippet's 2-digit number table   Yes
  India                                                                                                                                                                                           

  Luchesi et al. \[[@B19-biomolecules-07-00079]\]\           37                          86% (CAL)            Not mentioned                    Double-blinded     Computer-generated              Yes
  Brazil                                                                                                                                                                                          

  Dilsiz et al. \[[@B20-biomolecules-07-00079]\]\            24 (10/14)                  Not given            Not mentioned                    Double-blinded     Computer-generated              Yes
  Turkey                                                                                                                                                                                          

  Alwaeli et al. \[[@B32-biomolecules-07-00079]\]\           21 (7/14)                   Not given            Not mentioned                    Double-blinded     Computer-generated              No
  Malaysia                                                                                                                                                                                        

  Campanile et al. \[[@B27-biomolecules-07-00079]\]\         27 (14/13)                  80% (PD)             Not mentioned                    Single-blinded     Computer-generated              No
  Switzerland                                                                                                                                                                                     

  Bassir et al. \[[@B24-biomolecules-07-00079]\]\            16 (8/8)                    80% (PD)             Block randomization (size = 1)   Double-blinded     Computer-generated              Not mentioned
  USA                                                                                                                                                                                             

  Campos et al. \[[@B34-biomolecules-07-00079]\]\            15                          80% (PD)             Not mentioned                    Double-blinded     Computer-generated              Not mentioned
  Brazil                                                                                                                                                                                          

  Balata et al. \[[@B18-biomolecules-07-00079]\]\            22 (8/14)                   80% (CAL)            Not mentioned                    Not given          Coin toss                       Yes
  Brazil                                                                                                                                                                                          

  Barekdar et al. \[[@B21-biomolecules-07-00079]\]\          22 (12/10)                  Not mentioned        Not mentioned                    Single-blinded     Not mentioned                   Yes
  Germany                                                                                                                                                                                         

  Giannopoulou et al. \[[@B28-biomolecules-07-00079]\]\      32 (23/9)                   80% (PD)             Not mentioned                    Not mentioned      Computer-generated              No
  Switzerland                                                                                                                                                                                     

  Cappuyns et al. \[[@B29-biomolecules-07-00079]\]\          32 (23/9)                   80% (PD)             Not mentioned                    Single-blinded     Computer-generated              No
  Switzerland                                                                                                                                                                                     

  Lui et al. \[[@B22-biomolecules-07-00079]\]\               24 (10/14)                  Not mentioned        Not mentioned                    Single-blinded     Not mentioned                   Yes
  Hong Kong                                                                                                                                                                                       

  Theodoro et al. \[[@B25-biomolecules-07-00079]\]\          33 (12/21)                  81% (CAL)            Not mentioned                    Single-blinded     Computer-generated              Yes
  Brazil                                                                                                                                                                                          

  Sigush et al. \[[@B31-biomolecules-07-00079]\]\            24 (7/17)                   Not mentioned        Not mentioned                    Not given          Drawing lots                    Not mentioned
  Germany                                                                                                                                                                                         

  Ruhing et al. \[[@B30-biomolecules-07-00079]\]\            60                          80% (PD)             Not mentioned                    Single-blinded     Computer-generated              No
  Germany                                                                                                                                                                                         

  Christodoulides et al. \[[@B12-biomolecules-07-00079]\]\   24 (13/11)                  80% (PD)             Not mentioned                    Not given          Coin toss                       Yes
  Germany                                                                                                                                                                                         

  Braun et al. \[[@B11-biomolecules-07-00079]\]\             20 (9/11)                   Not mentioned        Not mentioned                    Single-blinded     Not mentioned                   Yes
  Germany                                                                                                                                                                                         

  Chondros et al. \[[@B13-biomolecules-07-00079]\]\          24 (10/14)                  80% (PD)             Not mentioned                    Single-blinded     Coin toss                       Yes
  Germany                                                                                                                                                                                         
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

biomolecules-07-00079-t003_Table 3

###### 

Laser parameters of the included studies.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author\                                                    Photosensitizer Concentration       Resident Time of Photosensitizer   Laser Application Time   Laser Wavelength   Laser Output   Fiber Optic Tip Diameter   Laser Energy
  Country                                                                                                                                                                                                                 
  ---------------------------------------------------------- ----------------------------------- ---------------------------------- ------------------------ ------------------ -------------- -------------------------- ---------------
  Kolbe et al. \[[@B26-biomolecules-07-00079]\]\             Methylene blue 10 mg/mL             1 min                              1 min                    660 nm             60 mw/cm^2^    Not mentioned              129 J
  Brazil                                                                                                                                                                                                                  

  Carvalho et al. \[[@B33-biomolecules-07-00079]\]\          Methylene blue 0.01%                5 min                              1 min                    660 nm             40 mw/cm^2^    Not mentioned              90 J
  Brazil                                                                                                                                                                                                                  

  Betsy et al. \[[@B23-biomolecules-07-00079]\]\             Methylene blue 10 mg/mL             3 min                              1 min                    655 nm             1 W/cm^2^      200 μm                     Not mentioned
  India                                                                                                                                                                                                                   

  Luchesi et al. \[[@B19-biomolecules-07-00079]\]\           Methylene blue 10 mg/mL             1 min                              1 min                    660 nm             60 mw/cm^2^    600 μm                     129 J
  Brazil                                                                                                                                                                                                                  

  Dilsiz et al. \[[@B20-biomolecules-07-00079]\]\            Methylene blue (25 g) 1%            3 min                              1 min                    808 nm             100 mw/cm^2^   300 μm                     6 J
  Turkey                                                                                                                                                                                                                  

  Alwaeli et al. \[[@B32-biomolecules-07-00079]\]\           Phenothiazine chloride              1 min                              1 min                    660 nm             100 mw/cm^2^   Not mentioned              Not mentioned
  Malaysia                                                                                                                                                                                                                

  Campanile et al. \[[@B27-biomolecules-07-00079]\]\         Methylene blue                      1 min                              1 min                    670 nm             280 mw/cm^2^   Not mentioned              Not mentioned
  Switzerland                                                                                                                                                                                                             

  Balata et al. \[[@B18-biomolecules-07-00079]\]\            Methylene blue 0.01%                2 min                              1 min                    660 nm             100 mw/cm^2^   Not mentioned              320 J
  Brazil                                                                                                                                                                                                                  

  Bassir et al. \[[@B24-biomolecules-07-00079]\]\            Toluidine blue O 0.1 mg/mL          3 min                              1 min                    635 nm             2 W/cm^2^      Not mentioned              Not mentioned
  USA                                                                                                                                                                                                                     

  Barekdar et al. \[[@B21-biomolecules-07-00079]\]\          Methylene blue 0.01%                2 min                              1 min                    670 nm             150 mw/cm^2^   600 μm                     Not mentioned
  Germany                                                                                                                                                                                                                 

  Giannelli et al. \[[@B39-biomolecules-07-00079]\]\         Methylene blue 0.03%                5 min                              1 min                    635 nm             100 mw/cm^2^   600 μm                     3.8 J
  Italy                                                                                                                                                                                                                   

  Giannopoulou et al. \[[@B28-biomolecules-07-00079]\]\      Phenothiazine chloride; 100 μg/mL   3 min                              1 min                    660 nm             100 mw/cm^2^   750 μm                     3 J
  Switzerland                                                                                                                                                                                                             

  Cappuyns et al. \[[@B29-biomolecules-07-00079]\]\          Phenothiazine chloride; 100 μg/mL   1 min                              1 min                    660 nm             40 mw/cm^2^    Not mentioned              Not mentioned
  Switzerland                                                                                                                                                                                                             

  Lui et al. \[[@B22-biomolecules-07-00079]\]\               Methylene blue 1%                   3 min                              30 s                     940 nm             1.5 W/cm^2^    Not mentioned              4 J
  Hong Kong                                                                                                                                                                                                               

  Theodoro et al. \[[@B25-biomolecules-07-00079]\]\          Toluidine blue O 100 μg/mL          1 min                              150 s                    660 nm             400 mw/cm^2^   Not mentioned              Not mentioned
  Brazil                                                                                                                                                                                                                  

  Sigush et al. \[[@B31-biomolecules-07-00079]\]\            Phenothiazine                       1 min                              1 min                    660 nm             60 mw/cm^2^    0.6 mm                     Not mentioned
  Germany                                                                                                                                                                                                                 

  Ruhing et al. \[[@B30-biomolecules-07-00079]\]\            Tolonium chloride 5%                Not mentioned                      1 min                    635 nm             100 mw/cm^2^   Not mentioned              Not mentioned
  Germany                                                                                                                                                                                                                 

  Christodoulides et al. \[[@B12-biomolecules-07-00079]\]\   Phenothiazine                       3 min                              1 min                    670 nm             75 mw/cm^2^    Not mentioned              Not mentioned
  Germany                                                                                                                                                                                                                 

  Braun et al. \[[@B11-biomolecules-07-00079]\]\             Phenothiazine                       3 min                              1 min                    660 nm             100 mw/cm^2^   Not mentioned              Not mentioned
  Germany                                                                                                                                                                                                                 

  Chondros et al. \[[@B13-biomolecules-07-00079]\]\          Phenothiazine                       Not mentioned                      1 min                    670 nm             75 mw/cm^2^    Not mentioned              Not mentioned
  Germany                                                                                                                                                                                                                 
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

biomolecules-07-00079-t004_Table 4

###### 

Studies reporting microbiologic, immunologic, and patient-based outcomes along with clinical parameters.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author\                                                 Sample Size   Outcome Measured                                                                                                                                Conclusions
  Country                                                                                                                                                                                                               
  ------------------------------------------------------- ------------- ----------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Kolbe et al. \[[@B26-biomolecules-07-00079]\]\          22            Microbiology(PCR); Pain perception (VAS)                                                                                                        Similar improvements noticed in clinical parameters with all treatments. PDT protocol presented inferior frequency of *P. gingivalis* at three months when compared with the other therapies. aPDT as an exclusive therapy may be considered a non-invasive alternative for treating residual pockets, offering advantages in the modulation of cytokines.
  Brazil                                                                                                                                                                                                                

  Carvalho et al. \[[@B33-biomolecules-07-00079]\]\       34            Microbiology(PCR); Pocket probing depth (PPD), CAL, BoP and PI                                                                                  All treatments resulted in significant clinical improvement in patients with residual periodontal pockets. PDT failed to show superior clinical results and pathogen load reduction in persistent pockets, compared to supragingival plaque control.
  Brazil                                                                                                                                                                                                                

  Betsy et al. \[[@B23-biomolecules-07-00079]\]\          90            Halitosis as perceived by patient                                                                                                               Changes in PD after three months and halitosis after one month. Gingival index and gingival bleeding index improved significantly in the test group after two weeks and one month of aPDT. As an adjunct to SRP, aPDT shows effectiveness in the short term for managing chronic periodontitis.
  India                                                                                                                                                                                                                 

  Luchesi et al. \[[@B19-biomolecules-07-00079]\]\        37            Microbiology (PCR); Immunology (GM-CSF, IFN-c, IL-6 and IL-8 levels)                                                                            Clinical parameters improved after both therapies. At six months, real-time PCR evaluation showed a decrease in *P. gingivalis* and *Tannerella forsythia* only in the PDT group, with no inter-group differences. IL-4 and IL-10 levels increased in both groups at six months. GM-CSF, IL-8, IL-1b and IL-6 levels decreased only in the PDT group after three months. At three months, inter-group analyses showed that GM-CSF, IFN-c, IL-6 and IL-8 levels were lower in the PDT group. At six months, lower IL-1b levels were also observed in the PDT group. Did not promote clinical benefits for class II furcations.
  Brazil                                                                                                                                                                                                                

  Campanile et al. \[[@B27-biomolecules-07-00079]\]\      27            Microbiology (PCR); Pain perception (VAS); Immunology (C-reactive protein, Serum amyloid A, fibrinogen, procalcitonin, and α-2 macroglobulin)   Detection frequencies of the studied microorganisms at \>1000 and \>100,000 cells/mL did not change significantly from baseline to months 3 or 6 in any group. Significant PD and BoP reduction after three months when aPDT given twice a week. C-reactive protein was significantly lower only if the laser had been activated twice.
  Switzerland                                                                                                                                                                                                           

  Cappuyns et al. \[[@B29-biomolecules-07-00079]\]\       32            Microbiology (RNA probes); Pain perception (VAS)                                                                                                Statistically significant PD and BoP reduction was seen at six months. Frequencies of three microorganisms were significantly lower in aPDT- and SRP-treated than in diode soft laser-treated quadrants after 14 days, but not at months 2 and 6. aPDT resulted in fewer residual pockets after six months.
  Switzerland                                                                                                                                                                                                           

  Giannopoulou et al. \[[@B28-biomolecules-07-00079]\]\   32            Immunology (IL-17, basic fibroblast growth factor, granulocyte colony-stimulating factor, and macrophage inflammatory protein 1-a)              No significant differences were observed among the three treatment modalities at any time point for any biochemical parameter or enhanced expression of inflammatory mediators.
  Switzerland                                                                                                                                                                                                           

  Theodoro et al. \[[@B25-biomolecules-07-00079]\]\       33            Microbiology (PCR)                                                                                                                              All treatment groups showed an improvement in all clinical parameters, and a significant reduction in the proportion of sites positive for periodontopathogens at 60, 90, and 180 d compared to the baseline. None of the periodontal parameters showed a significant difference among the groups. At 180 days, PDT treatment led to a significant reduction in the percentage of sites positive for all bacteria compared to SRP alone.
  Brazil                                                                                                                                                                                                                

  Lui et al. \[[@B22-biomolecules-07-00079]\]\            24            Immunology (IL-1b levels in gingival crevicular fluid)                                                                                          A significant decrease in gingival crevicular fluid volume was observed in both groups at one week, with a further decrease at one month in the test sites. The test sites showed a greater reduction of IL-1b levels in gingival crevicular fluid at one week than the control sites. No significant differences in periodontal parameters were found between the test and control teeth at three months.
  Hong Kong                                                                                                                                                                                                             

  Sigush et al. \[[@B31-biomolecules-07-00079]\]\         24            Microbiology (PCR)                                                                                                                              BoP, mean PD, and mean CAL showed improvement in the test group as compared to controls. aPDT may be used to manage periodontal inflammation and infection with *F. nucleatum*.
  Germany                                                                                                                                                                                                               

  Chondros et al. \[[@B13-biomolecules-07-00079]\]\       24            Microbiology (PCR)                                                                                                                              Application of a single episode of aPDT to SRP failed to result in an additional improvement. Significantly higher reduction of bleeding scores in test group. At three and six months, a statistically significantly higher improvement of BoP was found in the test group. At three months after therapy, the microbiological analysis showed a statistically significant reduction of *F. nucleatum* and *E. nodatum* in the test group.
  Germany                                                                                                                                                                                                               
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
